why choose us

First received: September 14, 2023

Clinical Trial: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Chronic Graft Versus Host Disease

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease

Brief Summary: This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Read more